Transpara
Transpara

The advance in deep learning radiologists have been waiting for

More powerful and more intelligent for 2D and 3D mammography

Introducing FusionAI®, the new platform which sets the standard for breast AI supported by clinical evidence. A fusion of knowledge: pathology, clinical imaging, X-ray physics and the latest deep learning techniques, uniquely combined by the scientists at ScreenPoint Medical in collaboration with our clinical partners.

Key facts and figures

up to 28%

more accurate 1

up to 35%

of exams with interval cancers found earlier 2

up to 70%

of exams can confidently be labelled as normal 3
Matches clinical performance of breast radiologists 4

1. Based on relative improvement vs 1.6.0 last year

2. Lång, K., Hofvind, S., Rodríguez-Ruiz, A. et al. Can artificial intelligence reduce the interval cancer rate in mammography screening?. Eur Radiol (2021). https://doi.org/10.1007/s00330-021-07686-3, A. Wanders, W. J. Mees, N. Janssen, A. Rodriguez-Ruiz, I. Sechopoulos, N. Karssemeijer, C. J. van Rooden, R. M. Mann. The Potential of AI for Improving Early Detection in Breast Cancer Screening to Reduce Interval Cancer Rates. Presented at RSNA 2020, publication pending

3. S. Romero Martín, J. Luis Raya Povedano, E. Elías Cabot, A. Gubern-Merida, A. Rodríguez-Ruiz, M. Álvarez Benito. Using autonomous AI to reduce the workload of breast cancer screening with breast tomosynthesis: a retrospective validation. Presented at RSNA 2020, publication pending

4. A. Rodriguez-Ruiz, E. Krupinski, J. Mordang, K. Schilling, S. Heywang-Kobrunner, I. Sechopoulos, R. Mann. Detection of breast cancer using mammography: Impact of an Artificial Intelligence support system. Radiology 2019;290 (2), 305-314, FDA approval number K193229.

Transpara 1.7.0 is CE marked and FDA cleared for 2D and 3D mammography. FDA approval number K210404. Some features may not be available in all countries, please check with your local representative.